Akkermansia muciniphila

Structure & Biochemistry

Taxonomy	Domain Bacteria → Phylum Verrucomicrobia → Class Verrucomicrobiae → Order Verrucomicrobiales → Family Akkermansiaceae → Akkermansia muciniphila
Cell morphology	Oval to short rod, ~1–2 µm; Gram-negative outer membrane; non-motile; non-spore-forming; strictly anaerobic; grows embedded in or adjacent to mucus layer
Amuc_1100	Heat-stable outer membrane protein; major TLR2/TLR4 ligand; mediates interaction with gut epithelium; pasteurised (non-live) form retains full biological activity — basis for pasteurised probiotic formulations
Mucin degradation arsenal	>50 predicted mucinases and glycosyl hydrolases (GH families 2, 18, 20, 25, 29, 33, 95); cleave O-glycan chains; harvest sugars and amino acids; by-products include propionate, acetate, formate
Short-chain fatty acid output	Primary products: propionate + acetate (from mucin fermentation); propionate activates GPR41/GPR43 on enteroendocrine cells → GLP-1 / PYY secretion → satiety signalling and insulin secretion
Pili / adhesins	Outer membrane proteins mediate mucin gel attachment; Amuc_1434 involved in mucus adhesion; specific S-layer absent (unlike some commensals)
Oxygen tolerance	Strictly anaerobic but more oxygen-tolerant than many gut anaerobes; survives briefly at oxic–anoxic interface near epithelium; 10⁻³ atm O₂ tolerated briefly
Genome	~2.7 Mb; ~2,136 predicted ORFs; large proportion encoding carbohydrate-active enzymes (CAZymes); GC content ~55.8%; single circular chromosome

Mechanisms of Benefit

• Mucus layer maintenance & gut barrier reinforcement Paradoxically, A. muciniphila degradation of mucins stimulates host goblet cells to increase MUC2 production, thickening the protective mucus layer. Amuc_1100 binding to TLR2 on colonocytes activates NF-κB and AP-1 modestly, upregulating claudin-3 and occludin — tight junction proteins — thereby reducing paracellular permeability and translocation of LPS into blood (metabolic endotoxaemia).
• Amuc_1100 → TLR2 → anti-inflammatory signalling Amuc_1100 is a potent TLR2 agonist (and moderate TLR4 agonist). Signalling through TLR2/TLR6 heterodimer shifts macrophage polarisation toward M2-like anti-inflammatory phenotype (IL-10↑, IL-12↓); promotes Treg induction via IL-10; reduces pro-inflammatory cytokines (TNF-α, IL-6) in adipose tissue — mechanistically explaining metabolic benefits observed in mouse and human studies.
• Metabolic axis: propionate → GLP-1 → insulin sensitivity Propionate produced from mucin/fibre fermentation activates free fatty acid receptors FFAR2 (GPR43) and FFAR3 (GPR41) on L-cells and enteroendocrine cells → GLP-1 and PYY secretion. GLP-1 enhances glucose-stimulated insulin secretion and promotes satiety. Obese and T2D patients consistently show <10-fold lower A. muciniphila abundance vs healthy controls; restoration by diet/berberine/metformin correlates with metabolic improvement.
• Outer membrane vesicles (OMVs) as paracrine signals A. muciniphila constitutively releases OMVs carrying Amuc_1100 and lipopolysaccharide-like structures (lacking classical endotoxic lipid A); OMVs enter the lamina propria and are taken up by macrophages and DCs, modulating cytokine milieu without evoking septic responses. OMV-mediated signalling active even at low bacterial abundance.
• Immunotherapy response potentiation Retrospective and prospective studies in cancer patients on checkpoint inhibitors (anti-PD-1) show that A. muciniphila-enriched microbiomes correlate with improved clinical response in NSCLC, RCC, and melanoma. Proposed mechanisms: IL-12 production from DCs, improved CD4+ T-cell infiltration of tumour, reduced regulatory T-cell suppression. Faecal microbiota transplant (FMT) from responders partially transfers the benefit in mouse models.

Microbiome Context & Host Associations

Clinical Associations

Condition	Association with A. muciniphila	Evidence Level	Direction
Type 2 Diabetes / Obesity	Reduced abundance in metabolic syndrome; supplementation improves insulin sensitivity and reduces adiposity markers in humans (RCT, 2019)	Phase 2 RCT	Beneficial
Inflammatory Bowel Disease	Depleted in active Crohn's and UC; whether this is cause or consequence of inflammation is debated; reduced mucus layer may increase bacterial translocation	Observational	Inverse
Colorectal Cancer	Lower abundance in CRC tissue vs healthy mucosa; potential protective via barrier effects; data inconsistent across cohorts	Observational	Inverse (tentative)
Checkpoint inhibitor response (cancer)	Higher A. muciniphila abundance associated with improved PFS in anti-PD-1 treated NSCLC and RCC; causal evidence from FMT mouse models	Human cohorts + mouse	Beneficial
Multiple Sclerosis	Elevated A. muciniphila in some MS cohorts; potential pro-inflammatory role in neuroinflammatory context; requires further study	Observational	Complex / unclear

Research Status & Therapeutic Potential

• Pasteurised A. muciniphila (WB-STR-0001) — next-generation probiotic Pasteurisation preserves Amuc_1100 and OMV activity while eliminating live-bacteria safety concerns. Phase 2 RCT (Plovier et al. concept; Cani group, 2019; n=32): pasteurised A. muciniphila 10¹⁰ CFU-equivalent/day reduced insulin resistance (HOMA-IR), visceral fat, and cardiometabolic risk factors. Pending Phase 3; EFSA novel food approval pathway underway in EU.
• Dietary modulation to increase abundance Dietary fibre (inulin, pectin, FOS), polyphenols (resveratrol, cranberry extracts, pomegranate), omega-3 fatty acids, and intermittent fasting all increase A. muciniphila in rodents and humans. Metformin and berberine also raise abundance; this contributes to their pleiotropic metabolic effects beyond direct pharmacological mechanisms.
• FMT and microbiome reconstitution context A. muciniphila abundance is used as a quality metric for FMT donor stools in metabolic disease trials. Transfer from healthy, A. muciniphila-rich donors to obese recipients shows transient engraftment and associated short-term metabolic improvement in some studies.

Cross-Atlas Connections

References

• Derrien M et al. (2004). Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54(5):1469–76.
• Plovier H et al. (2017). A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23(1):107–13.
• Depommier C et al. (2019). Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 25(7):1096–103.
• Routy B et al. (2018). Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359(6371):91–7.
• Cani PD, de Vos WM (2017). Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 8:1765.